Alumis

Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with immune-mediated diseases. The company focuses on a precision medicine approach, aiming to replace broad immunosuppression with targeted oral therapies. Alumis leverages its proprietary precision data analytics platform, which integrates genetic, genomic, proteomic, and clinical data, to identify optimal targets, molecules, and treatment combinations. This data-driven strategy is designed to select the right target, right molecule, right indication, right patient, and right endpoint, thereby optimizing therapeutic outcomes. Incubated by Foresite Labs, Alumis is led by an experienced team with a strong track record in precision medicine drug discovery, development, and immunology.

The company's pipeline includes next-generation treatments designed to address significant unmet needs in various autoimmune disorders. Alumis' most advanced product candidate, ESK-001, is an oral, highly selective, allosteric inhibitor of tyrosine kinase 2 (TYK2). ESK-001 has demonstrated promising results in a Phase 2 clinical trial for patients with moderate-to-severe plaque psoriasis (PsO) and is also being evaluated in a Phase 2 trial for systemic lupus erythematosus (SLE). Alumis is also developing A-005, a CNS-penetrant allosteric TYK2 inhibitor intended for neuroinflammatory and neurodegenerative diseases. The company's name, Alumis, is derived from 'allumer' (French for illuminate) and 'immunis' (Latin for the immune system), reflecting its mission to enlighten immunology. Recently, Alumis completed a merger with ACELYRIN, Inc., a move expected to strengthen its financial position and advance its late-stage pipeline. The combined entity will continue to operate under the Alumis name, with headquarters in South San Francisco, California.